Figure 1.

TSPAN1 is upregulated and TSPAN1 depletion decreases cell proliferation in human pancreatic cancer. (A) Representative immunohistochemical images of TSPAN1 expression in human pancreatic cancer tissues and normal pancreatic tissues and the quantification of TSPAN1 intensity. (B) Quantification of TSPAN1 expression in different stages of pancreatic cancer and normal pancreatic tissue samples. (C) Relative protein levels of TSPAN1 and LC3 in human normal pancreatic duct epithelial HPD E6-C7 cells and human pancreatic cancer PANC-1, ASPC-1, MIA-PACA-2, CAPAN-1 and SW1990 cells. (D) Kaplan-Meier overall survival curves for TSPAN1 in pancreatic cancer patients. (E and F) MTT assays were performed to examine the effect of TSPAN1 small interfering RNAs (#1, targeting CDS and #2, targeting 3ʹUTR) on cell viability. (G-I) DNA synthesis ability of the cells transfected with or without TSPAN1 siRNAs were assessed by EdU assays. (J and K) Colony formation assays were performed to assess the proliferation of cells transfected with or without TSPAN1 siRNAs. (L) Excised tumors in different groups were shown. (M) Growth curves showing the changes in the tumor volume in mice in different groups every 5 d from the injection. (N) Weight of the excised tumors in each group. (O) Representative H&E staining images and immunohistochemical images of MKI67 in excised tumors tissues. Data were represented as mean ± SD, *P < 0.05; **P < 0.01; ***P < 0.001